Teva Pharmaceutical Industries (NYSE:TEVA) Price Target Raised to $38.00

Teva Pharmaceutical Industries (NYSE:TEVA) had its target price lifted by Barclays from $35.00 to $38.00 in a research note published on Friday morning,Benzinga reports. Barclays currently has an overweight rating on the stock.

TEVA has been the subject of a number of other research reports. Wall Street Zen downgraded Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Sunday, January 18th. Piper Sandler increased their price target on shares of Teva Pharmaceutical Industries from $30.00 to $40.00 and gave the company an “overweight” rating in a research report on Monday, December 22nd. The Goldman Sachs Group boosted their price objective on shares of Teva Pharmaceutical Industries from $31.00 to $35.00 and gave the company a “buy” rating in a report on Friday, December 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, January 21st. Finally, Jefferies Financial Group boosted their price target on shares of Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday, January 6th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $36.00.

Teva Pharmaceutical Industries Stock Up 3.1%

Shares of NYSE TEVA opened at $34.08 on Friday. Teva Pharmaceutical Industries has a 1 year low of $12.47 and a 1 year high of $34.11. The firm’s 50-day moving average is $30.49 and its 200-day moving average is $23.25. The company has a current ratio of 1.11, a quick ratio of 0.82 and a debt-to-equity ratio of 2.31. The firm has a market capitalization of $39.09 billion, a PE ratio of 28.40, a price-to-earnings-growth ratio of 1.94 and a beta of 0.70.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Wednesday, January 28th. The company reported $0.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.31. The firm had revenue of $4.71 billion for the quarter, compared to analysts’ expectations of $4.36 billion. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 48.20%. The business’s revenue for the quarter was up 11.4% on a year-over-year basis. During the same period last year, the firm earned $0.71 earnings per share. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. Equities analysts expect that Teva Pharmaceutical Industries will post 2.5 EPS for the current year.

Insider Transactions at Teva Pharmaceutical Industries

In other news, insider Mark Sabag sold 216,892 shares of the firm’s stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $28.73, for a total transaction of $6,231,307.16. Following the completion of the transaction, the insider directly owned 52,828 shares of the company’s stock, valued at $1,517,748.44. This trade represents a 80.41% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Roberto Mignone sold 200,000 shares of the business’s stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $24.11, for a total transaction of $4,822,000.00. Following the completion of the sale, the director directly owned 495,000 shares in the company, valued at approximately $11,934,450. This represents a 28.78% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 622,060 shares of company stock valued at $17,076,965 in the last ninety days. Corporate insiders own 0.55% of the company’s stock.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Grove Bank & Trust grew its holdings in shares of Teva Pharmaceutical Industries by 300.0% in the 4th quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock valued at $31,000 after acquiring an additional 750 shares in the last quarter. Cromwell Holdings LLC increased its position in shares of Teva Pharmaceutical Industries by 40.3% during the 3rd quarter. Cromwell Holdings LLC now owns 2,191 shares of the company’s stock worth $44,000 after purchasing an additional 629 shares during the last quarter. Advisors Asset Management Inc. bought a new stake in shares of Teva Pharmaceutical Industries during the 2nd quarter worth approximately $41,000. Rothschild Investment LLC grew its stake in shares of Teva Pharmaceutical Industries by 97.0% in the third quarter. Rothschild Investment LLC now owns 2,738 shares of the company’s stock valued at $55,000 after buying an additional 1,348 shares in the last quarter. Finally, JFS Wealth Advisors LLC increased its holdings in Teva Pharmaceutical Industries by 257.1% during the third quarter. JFS Wealth Advisors LLC now owns 2,778 shares of the company’s stock worth $56,000 after buying an additional 2,000 shares during the last quarter. 54.05% of the stock is owned by institutional investors.

Key Teva Pharmaceutical Industries News

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Q4 fundamentals beat expectations — Teva reported stronger-than-expected results (reported EPS and revenue outperformed consensus), revenue grew year-over-year driven by a Sanofi milestone and Austedo growth, and management set FY‑2026 EPS guidance of roughly 2.57–2.77, supporting a higher valuation. TEVA’s Q4 Earnings Beat, Branded Drugs Drive Revenue Growth
• Positive Sentiment: Barclays raised its price target to $38 and set an “overweight” rating, signaling upside from current levels and lending third‑party validation to the stock’s outlook. Barclays raises TEVA price target to $38
• Positive Sentiment: Truist increased its price target to $38 with a “buy” rating, reinforcing bullish analyst sentiment following the quarter. Truist raises TEVA price target to $38
• Positive Sentiment: Scotiabank lifted its target to $40 and moved to “sector outperform,” the highest target among recent broker notes, which may attract more investor interest. Scotiabank raises TEVA price target to $40

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.